Trispecific 抗体学习 Sanofi 公司 2019年11月在《nature cancer》 发表文章 《三特异性抗体通过共激活T细胞受体提升定向肿瘤细胞治疗的效率 》,重新推出了 CD28 这个T细胞共激活靶点,是一篇经典的学习文章。 摘要 尽管治疗方法有了重大的进步,如免疫检查点和CAR-T等治疗方法,许多恶性肿瘤仍然对免疫治疗没有反应。同时...
介绍一种IL15-Trispecific Killer Engagers (TriKE) ,能够使自然杀伤细胞对CD33+靶点具有特异性,同时也诱导持久性、体内扩张和增强功能。 目的 输注NK细胞诱导白血病缓解的有效治疗受到抗原特异性和缺乏体内扩增的限制。为了解决第一个问题,作者...
Here, we developed a trispecific antibody that interacts with CD38, CD3 and CD28 to enhance both T cell activation and tumor targeting. The engagement of both CD3 and CD28 affords efficient T cell stimulation, whereas the anti-CD38 domain directs T cells to myeloma cells, as well as to ...
“We look forward to partnering with Simcere Zaiming, to advance this novel trispecific antibody, which has the potential to help address significant unmet medical needs for people living with multiple myeloma” “SIM0500 is developed via Simcere Zaiming’s...
Here, we evaluated in vivo efficacy and safety of the lead trispecific VHH-Fc, ABS-VIR-001. Importantly, our data showed that ABS-VIR-001 treatment prevented SARS-CoV-2 infection and death when provided as an intranasal prophylaxis in a humanized ACE-2 mouse model. In addition, ABS-VIR-...
Rational design of a trispecific antibody targeting the HIV-1 Env with elevated anti-viral activity HIV-1 broadly neutralizing antibodies (bNAbs) are being explored as passively administered therapeutic and preventative agents. However, the extensively di... JJ Steinhardt,J Guenaga,HL Turner,... -...
" saidMariana Cota Stirner, M.D., Ph.D., vice president, therapeutic area head for hematology, AbbVie. "We look forward to partnering with Simcere Zaiming, to advance this novel trispecific antibody, which has the potential to help addre...
Doer Bio published pre-clinical research results of the trispecific antibody DR30318 in Cancer Immunology, Immunotherapy2024.04.12On March 31, 2024, pre-clinical research results of the tri-specific antibody DR30318 independently developed by Zhejiang Doer Biologics Co., Ltd. (Doer Bio), were ...
DNA shuffling and ligation techniques were used to assemble and synthesize the 1615133 trispecific NK cell engager (TriKE). The construct was tested for its specificity using flow cytometry, cytotoxic determinations using chromium release assays, and lytic degranulation. IL-15–mediated expansion was ...
Aims: To evaluate CD38 as a potential therapeutic target in AML, and to determine the mode of action and preclinical efficacy of isatuximab (an IgG1 anti-CD38 mAb) and SAR442257, which is a new CD38/CD28xCD3 trispecific TCE. Results: We evaluated CD38 expression in bone marrow blasts fro...